Republican Cornyn & Democrat to continue inhumanity at Mexican border

egberto

6 years ago

Call: (646) 716-5812 – Facebook Live: PDRLive Live stream: BlogTalkRadio Radio Show Date: June 5th, 2018

It is time for Cornyn & Cuellar to get serious about real immigration reform the inhumanity and embarrassment at the border must stop.

You can also find previous episodes on YouTube here

Support Politics Done Right: Become a Patron now (http://patreon.com/politicsdoneright).

Daniel Cohen, President of Indivisible Houston returns to Politics Done Right to discuss the inhumanity at the Texas border as well as the sham bill Republican Senator John Cornyn and Democratic Congressman Henry Cuellar are trying to pass.

Our guest, Daniel Cohen’s article which is the blog of the week today, posted at both the Indivisible Houston website and at EgbertoWillies.com stated the following.

Cornyn’s office is bringing up an old bill- the Orwellian-titled “Humane Act” (SB 2611 in the Senate) from the 2013-2014 Congress- as a possible solution to child separation. In actuality, that bill does nothing to prevent children from separation. Rather, it pressures them into a 48-hour window in which CBP- the same institution that shot Claudia Gomez Gonzalez- would question children to determine if they need asylum before deporting them at a faster rate than ever before. Many of these guards do not speak any language other than English, and their role is not judiciary; they are neither fit nor humane enough in judgment to make asylum decisions, especially in two days time. An in-depth Vox report from the year the bill was introduced demonstrated that the process guards used to make sure children did not fall into the hands of traffickers was insufficient to the point of immoral negligence.

We will discuss this, the implications and what you can do.

From the Newsfeed

NBCNews: Billionaire entrepreneur, philanthropist and conservative activist David Koch is stepping down from his official capacities with the Koch organization due to declining health, leaving his brother Charles Koch as the sole family member to lead the company and their political and policy organizations. In a letter sent to employees at Koch Industries, the Nebraska-based energy and chemical company, Charles Koch told employees that David would be stepping down as “his health has continued to deteriorate.” “David has always been a fighter and is dealing with this challenge in the same way,” Charles wrote to employees. In addition to running Koch Industries, David helped to build a massive conservative network of donors that have built nearly a dozen organizations that work to organize voters and sway elected officials to support their libertarian-leaning economic policies. With David stepping down, however, Charles will continue to run the donor network. David’s health has been in decline for the past couple of years and he had slowly been stepping back from the organization. The network, led by Americans for Prosperity, has worked for years to elect candidates who hold similar views to local, state and national offices. They have spent more than $1 billion in the past several elections in support of candidates and policies that hew to their free-market and small government philosophy.

NBCNews: Seniors are paying more for name-brand drugs, while getting fewer of them, according to a new government report. The Inspector General’s Office of the Health and Human Services Department found that reimbursement costs for name-brand drugs obtained by patients through Medicare Part D plans jumped by 77 percent between 2011 and 2015, even though there was a drop of 17 percent in the number of prescriptions written for these drugs over that time period. The percentage of Medicare beneficiaries who have to pay more than $2,000 a year for name-brand drugs doubled over those years. Even when taking into account the rebates that pharmaceutical manufacturers offer, the OIG found that prices rose by 62 percent. “That’s a very meaningful result,” said Paul Ginsburg, director of the center for health policy at the Brookings Institution and professor of health policy at the University of Southern California. “Often, when the pharmaceutical industry responds to data on price increases, they say, ‘Oh, that’s before rebates,’ but this study actually adjusted for rebates and still found very substantial price increases,” he said. Health policy and market experts say pharmacy benefit managers, or PBMs for short, bear part of the blame. PBMs act as middlemen between insurance company plan administrators and drug companies. They negotiate for lower prices and rebates on drug costs, but it’s not clear how much of those savings are ultimately passed on to patients.